Related references
Note: Only part of the references are listed.Reference standards for gene fusion molecular assays on cytological samples: an international validation study
Umberto Malapelle et al.
JOURNAL OF CLINICAL PATHOLOGY (2023)
Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling
Albrecht Stenzinger et al.
SEMINARS IN CANCER BIOLOGY (2022)
Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing
Esther Conde et al.
JOURNAL OF CLINICAL PATHOLOGY (2022)
IHC versus FISH versus NGS to detect ALK gene rearrangement in NSCLC: all questions answered?
Ullas Batra et al.
JOURNAL OF CLINICAL PATHOLOGY (2022)
Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy
Erin Faber et al.
JOURNAL OF CLINICAL PATHOLOGY (2022)
Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe
Denis Horgan et al.
JOURNAL OF PERSONALIZED MEDICINE (2022)
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma
Jan Budczies et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)
Utilization Trends and Factors Associated With ROS1 Testing Among Patients With Advanced Non-small-cell Lung Cancer in US Community Practices
William Wong et al.
CLINICAL LUNG CANCER (2021)
Current and future applications of artificial intelligence in pathology: a clinical perspective
Emad A. Rakha et al.
JOURNAL OF CLINICAL PATHOLOGY (2021)
Cytomorphology of primary pulmonary NUT carcinoma in different cytology preparations
Rimlee Dutta et al.
CANCER CYTOPATHOLOGY (2021)
ROS1-dependent cancers - biology, diagnostics and therapeutics
Alexander Drilon et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib
Ezra Y. Rosen et al.
CLINICAL CANCER RESEARCH (2021)
NTRK Fusion-positive Non-small-cell Lung Cancer: The Diagnosis and Targeted Therapy
Naoki Haratake et al.
CLINICAL LUNG CANCER (2021)
Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung Cancer
Mohammad Jahanzeb et al.
CLINICAL LUNG CANCER (2021)
Prevalence and potential biological role of TERT amplifications in ALK translocated adenocarcinoma of the lung
Christina Alidousty et al.
HISTOPATHOLOGY (2021)
Efficacy and Safety of Neoadjuvant Targeted Therapy vs. Neoadjuvant Chemotherapy for Stage IIIA EGFR-Mutant Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Dong Chen et al.
FRONTIERS IN SURGERY (2021)
Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study
Tony Mok et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Therapeutic Potential of Afatinib inNRG1Fusion-Driven Solid Tumors: A Case Series
Jacques Cadranel et al.
ONCOLOGIST (2021)
ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research
C. Belli et al.
ANNALS OF ONCOLOGY (2021)
Lorlatinib in ALK-Rearranged Lung Cancer
Shelley Kuang et al.
CANCER CELL (2021)
FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions
Diana Bradford et al.
CLINICAL CANCER RESEARCH (2021)
Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression
Azusa Tanimoto et al.
CLINICAL CANCER RESEARCH (2021)
ALK Rearrangement in Lung Neuroendocrine Neoplasms: Case Series of Non-Asian Patients With Response to ALK Inhibitors
Helene Doubre et al.
CLINICAL LUNG CANCER (2021)
Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer
Diego Kauffmann-Guerrero et al.
DRUGS (2021)
Accurate and efficient detection of gene fusions from RNA sequencing data
Sebastian Uhrig et al.
GENOME RESEARCH (2021)
Thoracic nuclear protein in testis (NUT) carcinoma: expanded pathological spectrum with expression of thyroid transcription factor-1 and neuroendocrine markers
Yin P. Hung et al.
HISTOPATHOLOGY (2021)
Lung Adenocarcinoma With Primary LIMD1-BRAF Fusion Treated With MEK Inhibitor: A Case Report
Cheng-You Wang et al.
CLINICAL LUNG CANCER (2021)
Clinicopathologic, genomic and protein expression characterization of 356 ROS1 fusion driven solid tumors cases
Richard S. P. Huang et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer
Hedvig Elfving et al.
LUNG CANCER (2021)
Supercharging BRD4 with NUT in carcinoma
Kyle P. Eagen et al.
ONCOGENE (2021)
Update on genetically defined lung neoplasms: NUT carcinoma and thoracic SMARCA4-deficient undifferentiated tumors
Kyriakos Chatzopoulos et al.
VIRCHOWS ARCHIV (2021)
Cytology samples and molecular biomarker testing in lung cancer-advantages and challenges
Sule Canberk et al.
VIRCHOWS ARCHIV (2021)
Upfront Management of ALK-Rearranged Metastatic Non-small Cell Lung Cancer: One Inhibitor Fits All?
Fabrizio Tabbo et al.
CURRENT ONCOLOGY REPORTS (2021)
RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer
Caterina De Luca et al.
CANCERS (2021)
Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine Practice
Paul Hofman
CELLS (2021)
RNA-Based Multiplexing Assay for Routine Testing of Fusion and Splicing Variants in Cytological Samples of NSCLC Patients
Cristina Aguado et al.
DIAGNOSTICS (2021)
Therapeutic Sequencing in ALK(+) NSCLC
Mei Elsayed et al.
PHARMACEUTICALS (2021)
Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations
V Subbiah et al.
ANNALS OF ONCOLOGY (2021)
Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer
V. Subbiah et al.
ANNALS OF ONCOLOGY (2021)
Detection of gene fusions using targeted next-generation sequencing: a comparative evaluation
Carina Heydt et al.
BMC MEDICAL GENOMICS (2021)
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
Christian Rolfo et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Predictive 'biomarker piggybacking': an examination of reflexive pan-cancer screening with pan-TRK immunohistochemistry
Lynette M. Sholl et al.
HISTOPATHOLOGY (2021)
Comprehensive genetic profiling of six pulmonary nuclear protein in testis carcinomas with a novel micropapillary histological subtype in two cases
Min Chen et al.
HUMAN PATHOLOGY (2021)
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
Nasser H. Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer
Rafal Dziadziuszko et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Prospective Multicenter Validation of the Detection of ALK Rearrangements of Circulating Tumor Cells for Noninvasive Longitudinal Management of Patients With Advanced NSCLC
Marius Ilie et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
RET Fluorescence In Situ Hybridization Analysis Is a Sensitive but Highly Unspecific Screening Method for RET Fusions in Lung Cancer
Teodora Radonic et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC
Weihua Li et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Noncanonical Gene Fusions Detected at the DNA Level Necessitate Orthogonal Diagnosis Methods Before Targeted Therapy
Zhengbo Song et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)
Frank Griesinger et al.
LUNG CANCER (2021)
ALK-rearranged squamous cell carcinoma of the lung
Qiyi Meng et al.
THORACIC CANCER (2021)
Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer
Yunfei Shi et al.
CANCER MEDICINE (2021)
Challenges and Opportunities in NUT Carcinoma Research
Bin Gu et al.
GENES (2021)
Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA
C. M. Della Corte et al.
ESMO OPEN (2021)
Actionable driver DNA variants and fusion genes can be detected in archived cytological specimens with the Oncomine Dx Target Test Multi-CDx system in lung cancer
Kenji Amemiya et al.
CANCER CYTOPATHOLOGY (2021)
The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions
Igor Odintsov et al.
CLINICAL CANCER RESEARCH (2021)
Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer
Theodore W. Laetsch et al.
CLINICAL CANCER RESEARCH (2021)
Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake
Alessandro De Toma et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
Identification of novel ALK fusions using DNA/RNA sequencing in immunohistochemistry/RT-PCR discordant NSCLC patients
Bei Wang et al.
HUMAN PATHOLOGY (2021)
NTRK fusions and Trk proteins: what are they and how to test for them
Lawrence M. Weiss et al.
HUMAN PATHOLOGY (2021)
The genomic landscape of young and old lung cancer patients highlights age-dependent mutation frequencies and clinical actionability in young patients
Lei Cai et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers
Igor Odintsov et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
NRG1 fusions: Biology to therapy
Stephen V. Liu
LUNG CANCER (2021)
Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis
Arlou Kristina Angeles et al.
NPJ PRECISION ONCOLOGY (2021)
The Promising Evolution of Targeted Therapeutic Strategies in Cancer
Solange Peters et al.
CANCER DISCOVERY (2021)
Applicability of pan-TRK immunohistochemistry for identification of NTRK fusions in lung carcinoma
Simon Strohmeier et al.
SCIENTIFIC REPORTS (2021)
Immunotherapy for ALK-Rearranged Non-Small Cell Lung Cancer: Challenges Inform Promising Approaches
Kamya Sankar et al.
CANCERS (2021)
Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations
Antonio Passaro et al.
CANCERS (2021)
Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer
Laura Pacini et al.
CELLS (2021)
Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer
Mei Elsayed et al.
FRONTIERS IN ONCOLOGY (2021)
Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population
Ruiying Zhao et al.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH (2021)
FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions
Janice Kim et al.
CLINICAL CANCER RESEARCH (2021)
Prolonged Disease Control on Nivolumab for Primary Pulmonary NUT Carcinoma
Alexander Davis et al.
CLINICAL LUNG CANCER (2021)
Validation of ROS1 by immunohistochemistry against fluorescent in situ hybridisation on cytology and small biopsy samples in a large teaching hospital
Nadira Narine et al.
CYTOPATHOLOGY (2021)
Efficacy of immune checkpoint inhibitor therapy in patients with RET fusion-positive non-small-cell lung cancer
Naleen Raj Bhandari et al.
IMMUNOTHERAPY (2021)
Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry
Alexander Drilon et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Diagnostic Utility of Gene Fusion Panel to Detect Gene Fusions in Fresh and Formalin-Fixed, Paraffin-Embedded Cancer Specimens
Lisa Haley et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2021)
SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition
Joao V. Alessi et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancers
Peiyi Xia et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2021)
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
Justin F. Gainor et al.
LANCET ONCOLOGY (2021)
Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK plus ) NSCLC
Shannon S. Zhang et al.
LUNG CANCER (2021)
NUT carcinoma of the lung
Sylvie Lantuejoul et al.
SEMINARS IN DIAGNOSTIC PATHOLOGY (2021)
Status quo of ALK testing in lung cancer: results of an EQA scheme based on in-situ hybridization, immunohistochemistry, and RNA/DNA sequencing
Philipp Jurmeister et al.
VIRCHOWS ARCHIV (2021)
A Novel KIF5B-EGFR Fusion Variant in Non-Small-Cell Lung Cancer and Response to Afatinib: A Case Report
Xia Wang et al.
ONCOTARGETS AND THERAPY (2021)
Perspectives and Issues in the Assessment of SMARCA4 Deficiency in the Management of Lung Cancer Patients
Subasri Armon et al.
CELLS (2021)
Peripheral Lung Squamous Carcinoma With ROS1 Rearrangement Sensitive to Crizotinib: A Case Report
Guangdie Yang et al.
FRONTIERS IN ONCOLOGY (2021)
Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue
Shinkichi Takamori et al.
FRONTIERS IN ONCOLOGY (2021)
Detection of ALK fusion transcripts in plasma of non-small cell lung cancer patients using a novel RT-PCR based assay
Simon Heeke et al.
ANNALS OF TRANSLATIONAL MEDICINE (2021)
Pan-TRK Immunohistochemistry An Example-Based Practical Approach to Efficiently Identify Patients With NTRK Fusion Cancer
Esther Conde et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2021)
Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies
Petros Christopoulos et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2021)
Out-of-Pocket Costs for Tyrosine Kinase Inhibitors and Patient Outcomes in EGFR- and ALK-Positive Advanced Non-Small-Cell Lung Cancer
Bernardo H. L. Goulart et al.
JCO ONCOLOGY PRACTICE (2021)
The Road Less Traveled: A Guide to Metastatic ROS1-Rearranged Non-Small-Cell Lung Cancer
Daniel Almquist et al.
JCO ONCOLOGY PRACTICE (2021)
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program
Nikolaj Frost et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)
Targeted Next-Generation Sequencing Analysis for Recurrence in Early-Stage Lung Adenocarcinoma
In Ae Kim et al.
ANNALS OF SURGICAL ONCOLOGY (2021)
Correlation of ROS1 Immunohistochemistry With ROS1 Fusion Status Determined by Fluorescence In Situ Hybridization
Richard S. P. Huang et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2020)
NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls
James P. Solomon et al.
MODERN PATHOLOGY (2020)
The pre-analytical phase of the liquid biopsy
Francesca Salvianti et al.
NEW BIOTECHNOLOGY (2020)
Testing NTRK testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assays
Nicole Pfarr et al.
GENES CHROMOSOMES & CANCER (2020)
State-of-the-Art Strategies for Targeting RET-Dependent Cancers
Vivek Subbiah et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Artificial intelligence as the next step towards precision pathology
B. Acs et al.
JOURNAL OF INTERNAL MEDICINE (2020)
Clinicopathologic Characteristics of BRG1-De fi cient NSCLC
Ibiayi Dagogo-Jack et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
David S. Hong et al.
LANCET ONCOLOGY (2020)
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Robert C. Doebele et al.
LANCET ONCOLOGY (2020)
Specialized Blood Collection Tubes for Liquid Biopsy: Improving the Pre-analytical Conditions
Laure Sorber et al.
MOLECULAR DIAGNOSIS & THERAPY (2020)
Sequencing Strategies for Fusion Gene Detection
Erin E. Heyer et al.
BIOESSAYS (2020)
NTRK testing: First results of the QuiP-EQA scheme and a comprehensive map of NTRK fusion variants and their diagnostic coverage by targeted RNA-based NGS assays
Martina Kirchner et al.
GENES CHROMOSOMES & CANCER (2020)
Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement
Jan Budczies et al.
LUNG CANCER (2020)
VPS41-BRAF, a novel BRAF fusion gene identified in a lung adenocarcinoma patient by next-generation sequencing
Lujuan Wang et al.
LUNG CANCER (2020)
Imaging-Based Prediction of Molecular Therapy Targets in NSCLC by Radiogenomics and AI Approaches: A Systematic Review
Gaia Ninatti et al.
DIAGNOSTICS (2020)
Artificial Intelligence in Pathology: A Simple and Practical Guide
Keluo Yao et al.
ADVANCES IN ANATOMIC PATHOLOGY (2020)
The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer
Adamj. Schoenfeld et al.
CLINICAL CANCER RESEARCH (2020)
Deep Learning for the Classification of Small-Cell and Non-Small-Cell Lung Cancer
Mark Kriegsmann et al.
CANCERS (2020)
Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer
J. J. Lin et al.
ANNALS OF ONCOLOGY (2020)
NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents
J. Laskin et al.
ANNALS OF ONCOLOGY (2020)
Challenges in the Diagnosis of NTRK Fusion-Positive Cancers
Oliver Gautschi et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Effects ofex vivoischemia time and delayed processing on quality of specimens in tissue biobank
Dan Guo et al.
MOLECULAR MEDICINE REPORTS (2020)
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
KIF5B-EGFR Fusion: A Novel EGFR Mutation in Lung Adenocarcinoma
Hui Xu et al.
ONCOTARGETS AND THERAPY (2020)
Clinicopathological characteristics of primary lung nuclear protein in testis carcinoma: A single-institute experience of 10 cases
Yoon Ah Cho et al.
THORACIC CANCER (2020)
Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA
Steffen Dietz et al.
EBIOMEDICINE (2020)
Narrative review of molecular pathways of kinase fusions and diagnostic approaches for their detection in non-small cell lung carcinomas
Matthias S. Matter et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
Decade in review: a new era for RET-rearranged lung cancers
Noura J. Choudhury et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
How selecting best upfront therapy for metastatic disease?-Focus on ROS1-rearranged disease
Lorenza Landi et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung Cancer
Laura Mezquita et al.
JCO PRECISION ONCOLOGY (2020)
Hyper-progressive disease after immune checkpoint inhibitor in SMARCA4-deficient small-cell lung carcinoma
Yosuke Chiba et al.
RESPIROLOGY CASE REPORTS (2020)
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
F. Mosele et al.
ANNALS OF ONCOLOGY (2020)
Identification of a highly lethal V3+TP53+ subset in ALK+ lung adenocarcinoma
P. Christopoulos et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling
Angel Qin et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
A Patient With Lung Adenocarcinoma With BRAF Gene Fusion and Response to Vemurafenib
You-cai Zhu et al.
CLINICAL LUNG CANCER (2019)
Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers
Morana Vojnic et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
The challenges of evaluating predictive biomarkers using small biopsy tissue samples and liquid biopsies from non-small cell lung cancer patients
Paul Hofman
JOURNAL OF THORACIC DISEASE (2019)
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J. Mazieres et al.
ANNALS OF ONCOLOGY (2019)
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden
Ryma Benayed et al.
CLINICAL CANCER RESEARCH (2019)
Multicenter Evaluation of a Novel ROS1 Immunohistochemistry Assay (SP384) for Detection of ROS1 Rearrangements in a Large Cohort of Lung Adenocarcinoma Patients
Veronique Hofman et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
A study of ALK-positive pulmonary squamous-cell carcinoma: From heck for diagnostic methodologies to clinical efficacy
Haiyue Wang et al.
LUNG CANCER (2019)
Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer
Chen Lin et al.
LUNG CANCER (2019)
Pre-analytical processes in medical diagnostics: New regulatory requirements and standards
Georges Dagher et al.
NEW BIOTECHNOLOGY (2019)
Effectiveness of EGFR-TKIs in a Patient with Lung Adenocarcinoma Harboring an EGFR-RAD51 Fusion
Yan Guan et al.
ONCOLOGIST (2019)
ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research
C. Marchio et al.
ANNALS OF ONCOLOGY (2019)
Preanalytics and Precision Pathology Pathology Practices to Ensure Molecular Integrity of Cancer Patient Biospecimens for Precision Medicine
Carolyn C. Compton et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2019)
Detection of NTRK Fusions: Merits and Limitations of Current Diagnostic Platforms
James P. Solomon et al.
CANCER RESEARCH (2019)
Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts
Daniel Kazdal et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study
Esther Conde et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Detection of Novel NRG1, EGFR, and MET Fusions in Lung Adenocarcinomas in the Chinese Population
Yunjian Pan et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Identification of a Novel Icotinib-Sensitive EGFR-SEPTIN14 Fusion Variant in Lung Adenocarcinoma by Next-Generation Sequencing
You-cai Zhu et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA
Julianna G. Supplee et al.
LUNG CANCER (2019)
Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
A. Amatu et al.
ANNALS OF ONCOLOGY (2019)
Artificial Intelligence in Lung Cancer Pathology Image Analysis
Shidan Wang et al.
CANCERS (2019)
Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins
Dana S. Neel et al.
CANCER RESEARCH (2019)
Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases
Anna-Lena Volckmar et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer
Charu Aggarwal et al.
JAMA ONCOLOGY (2019)
Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1-ALK-rearranged lung cancer
Steffen Dietz et al.
COLD SPRING HARBOR MOLECULAR CASE STUDIES (2019)
Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies
Justin I. Odegaard et al.
CLINICAL CANCER RESEARCH (2018)
Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib
Nobuyoshi Hayashi et al.
INTERNAL MEDICINE (2018)
EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK(+) non-small cell lung cancer
Petros Christopoulos et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
Jessica J. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Rediagnosis of Lung Cancer as NUT Midline Carcinoma Based on Clues From Tumor Genomic Profiling
Alexander S. Baras et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
EGFR-RAD51 Fusion: A Targetable Partnership Originated from the Tumor Evolution?
Luis E. Raez et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors
Alexa B. Schrock et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer
Ziming Li et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples
Kurtis D. Davies et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer
Roberto Ferrara et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
EGFR-RAD51 fusion variant in lung adenocarcinoma and response to erlotinib: A case report
You-cai Zhu et al.
LUNG CANCER (2018)
EML4-ALK V3, treatment resistance, and survival: refining the diagnosis of ALK+ NSCLC
Petros Christopoulos et al.
JOURNAL OF THORACIC DISEASE (2018)
Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study
Cecily P. Vaughn et al.
BMC CANCER (2018)
Clinical utility of reflex testing using focused next-generation sequencing for management of patients with advanced lung adenocarcinoma
Tyler E. Miller et al.
JOURNAL OF CLINICAL PATHOLOGY (2018)
Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics
Ryosuke Okamura et al.
JCO PRECISION ONCOLOGY (2018)
BRAF in Lung Cancers: Analysis of Patient Cases Reveals Recurrent BRAF Mutations, Fusions, Kinase Duplications , and Concurrent Alterations
Yuri Sheikine et al.
JCO PRECISION ONCOLOGY (2018)
Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors Through Longitudinal Analysis of Circulating Tumor DNA
Ibiayi Dagogo-Jack et al.
JCO PRECISION ONCOLOGY (2018)
Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion
Anna F. Farago et al.
JCO PRECISION ONCOLOGY (2018)
Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients
Zhengbo Song et al.
CANCER BIOLOGY & THERAPY (2017)
Spatial distribution of EGFR and KRAS mutation frequencies correlates with histological growth patterns of lung adenocarcinomas
Steffen Dietz et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
DNA degrades during storage in formalin-fixed and paraffin-embedded tissue blocks
Alice Guyard et al.
VIRCHOWS ARCHIV (2017)
ALK Status Assessment with Liquid Biopsies of Lung Cancer Patients
Paul Hofman
CANCERS (2017)
ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice
Paul Hofman
CANCERS (2017)
Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology
Paul Hofman
CANCERS (2017)
Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions
Jaclyn F. Hechtman et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2017)
Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer
Anna F. Farago et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2017)
ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature
Nobuaki Mamesaya et al.
BMC CANCER (2017)
High-Throughput Diagnostic Profiling of Clinically Actionable Gene Fusions in Lung Cancer
Nicole Pfarr et al.
GENES CHROMOSOMES & CANCER (2016)
The distribution of BRAF gene fusions in solid tumors and response to targeted therapy
Jeffrey S. Ross et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare
Weijie Zhao et al.
LUNG CANCER (2016)
EGFR Fusions as Novel Therapeutic Targets in Lung Cancer
Kartik Konduri et al.
CANCER DISCOVERY (2016)
FGFR3-TACC3 fusion in solid tumors: mini review
Ricardo Costa et al.
ONCOTARGET (2016)
NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma
Michael Duruisseaux et al.
CANCER MEDICINE (2016)
Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma
Weijing Cai et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non-Small Cell Lung Cancer
Rui Wang et al.
CLINICAL CANCER RESEARCH (2014)
Molecular Mechanisms Underlying Oncogenic RET Fusion in Lung Adenocarcinoma
Tatsuji Mizukami et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Detection of Circulating Tumor Cells Harboring a Unique ALK Rearrangement in ALK-Positive Non-Small-Cell Lung Cancer
Emma Pailler et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Can we eliminate squamous cell carcinoma of the lung from testing of EML4-ALK fusion gene?
Nobuaki Ochi et al.
LUNG CANCER (2013)
Identification of Targetable FGFR Gene Fusions in Diverse Cancers
Yi-Mi Wu et al.
CANCER DISCOVERY (2013)
The transcriptional landscape and mutational profile of lung adenocarcinoma
Jeong-Sun Seo et al.
GENOME RESEARCH (2012)
Preparing pathology for personalized medicine: possibilities for improvement of the pre-analytical phase
Patricia J. T. A. Groenen et al.
HISTOPATHOLOGY (2011)
Long-Term Survival of a Patient with Squamous Cell Carcinoma Harboring NUT Gene Rearrangement
Naomi Fujioka et al.
JOURNAL OF THORACIC ONCOLOGY (2010)